Promedior, Inc., today announced positive bone marrow fibrosis data from Stage 1 of an adaptive two-stage Phase 2 trial of PRM-151, a novel anti-fibrotic immunotherapy, in patients with myelofibrosis. These newly-presented data demonstrate a reduction of bone marrow fibrosis in 72 percent of patients receiving PRM-151 according to Computer Image Analysis (CIA), which was highly correlated with, but more sensitive than, the WHO myelofibrosis grade. Reduction in bone marrow fibrosis in patients receiving PRM-151 was associated with other improvements in bone marrow morphology, as well as increased platelet counts and increased hemoglobin. In this study, 57 percent of thrombocytopenic patients receiving PRM-151 saw an improvement in their platelet counts. These study results were described in a poster presentation at the 20th Congress of the European Hematology Association in Vienna, Austria.